Spirovant Sciences today appointed Roland Kolbeck, PhD, as Chief Scientific Officer. Dr. Kolbeck is an accomplished biotech executive, specializing in respiratory sciences and drug discovery with 20+ years of research and executive leadership experience, most recently at MedImmune, AstraZeneca’s global biologics organization.
Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis (CF), today appointed Roland Kolbeck, PhD, as Chief Scientific Officer. Dr. Kolbeck is an accomplished biotech executive, specializing in respiratory sciences and drug discovery.
Philadelphia gene therapy company Spirovant Sciences changed owners twice in 2019— including being acquired by Sumitomo Dainippon Pharma of Japan last week as part of a $3 billion deal — and its CEO couldn’t be happier.
Effective December 27, 2019, DSP has acquired from Roivant 100% of “Sumitovant Biopharma,” a newly formed company, and Roivant’s ownership interest in the five subsidiary companies, including Spirovant, that comprise Sumitovant.
Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading Japanese pharmaceutical company, and Roivant Sciences Ltd., a technology-enabled healthcare company, today announced that they have signed a definitive agreement for the creation of a novel and broad Strategic Alliance and […]
As part of a $3 billion deal brokered with Roivant Sciences, Japanese drugmaker Sumitomo Dainippon will gain ownership of Spirovant, a newly unveiled biotech focused on developing gene therapies for cystic fibrosis.